Skip to main content
. Author manuscript; available in PMC: 2009 Oct 14.
Published in final edited form as: AIDS Patient Care STDS. 2009 Oct;23(10):815–824. doi: 10.1089/apc.2009.0048

Table 2.

Demographic, Laboratory, and Clinical Factors in Relation to the Risk of Presence of Coronary Plaques *

Variable All Plaques Noncalcified Plaques Calcified Plaques
Crude OR (95% CI) Adjusted OR (95% CI) Crude OR (95% CI) Adjusted OR (95% CI) Crude OR (95% CI) Adjusted OR (95% CI)
Age (y)
 <50 1.00 1.00 1.00 1.00
 ≥50 4.35 (1.66, 11.4) 3.11 (1.04,9.30) 3.00 (0.87, 10.4) 3.05 (1.14, 8.15)
Sex
 Female 1.00 1.00 1.00 1.00 1.00
 Male 3.35 (1.54, 7.27) 4.23 (1.79, 10.0) 1.85 (0.57, 5.99) 3.64 (1.43, 9.31) 4.32 (1.60, 11.7)
Family history of CAD
 No 1.00 1.00 1.00
 Yes 1.26 (0.61, 2.66) 2.07 (0.70, 6.07) 0.89 (0.37, 2.14)
CD4 count (cells/mm3)
 >200 1.00 1.00 1.00
 ≤200 0.74 (0.28, 1.95) 0.24 (0.01, 1.77) 1.29 (0.44, 3.74)
HIV RNA (copies/mL)
 <400 1.00 1.00 1.00
 ≥400 1.26 (0.52, 3.02) 5.40 (1.10, 26.4) 0.50 (0.17, 1.46)
Cocaine use
 Never 1.00 1.00 1.00
 Ever 3.18 (0.70, 14.5) 0.67(0.14, 3.26) not estimable
Years of cocaine use
 ≤15 1.00 1.00 1.00 1.00 1.00
 >15 2.65 (1.35,5.18) 2.67 (1.23, 5.83) 0.75 (0.97, 7.79) 2.02 (0.96, 4.26) 2.51 (1.11, 5.67)
Cigarette smoking
 Never 1.00 1.00 1.00
 Ever 1.30 (0.49, 3.49) 1.12 (0.24, 5.25) 1.33 (0.43, 4.18)
Years of cigarette smoking
 ≤15 1.00 1.00 1.00
 >15 1.83 (0.78, 4.32) 1.26 (0.34, 4.66) 1.99 (0.71, 5.52)
Alcohol use
 No 1.00 1.00 1.00
 Yes 1.53 (0.48, 4.88) 1.78 (0.22, 14.4) 1.32 (0.36, 4.83)
hsCRP (mg/dL)
 <2 1.00 1.00 1.00
 ≥2 0.86 (0.44, 1.68) 0.82 (0.29, 2.38) 0.92 (0.43, 1.95)
Systolic BP (mm Hg)
 <120 1.00 1.00 1.00
 ≥120 1.36 (0.64, 2.87) 0.74 (0.20, 2.72) 1.68 (0.74,3.82)
Diastolic BP (mm Hg)
 ≤80 1.00 1.00 1.00
 >80 1.64 (0.82, 3.28) 2.97 (0.69, 5.61) 1.30 (0.59, 2.87)
Glucose (mg/dL)
 <85 1.00 1.00 1.00
 ≥85 1.56 (0.81, 3.00) 2.17 (0.75, 6.27) 1.19 (0.57, 2.50)
BMI (kg/m2)
 <24 1.00 1.00 1.00
 ≥24 0.87 (0.45, 1.68) 0.59 (0.20, 1.69) 1.11 (0.53, 2.33)
Total cholesterol (mg/dL)
 <160 1.00 1.00 1.00 1.00
 ≥160 2.51 (1.27, 4.96) 2.47 (1.16, 5.27) 3.20 (0.99, 10.3) 1.84 (0.86, 3.95)
LDL-C (mg/dL)
 <100 1.00 1.00 1.00
 ≥100 1.83 (0.93, 3.60) 1.57 (0.55, 4.45) 1.71 (0.79, 3.66)
HDL-C (mg/dL)
 <50 1.00 1.00 1.00
 ≥50 0.78 (0.41, 1.50) 0.94 (0.34, 2.63) 0.75 (0.36, 1.58)
Triglycerides (mg/dL)
 <130 1.00 1.00 1.00 1.00
 ≥130 2.54 (1.30, 4.98) 1.10 (0.38, 3.20) 3.11 (1.45, 6.66) 3.39 (1.52, 7.57)
Framingham score
 <3% 1.00 1.00 1.00
 ≥3% 5.68 (2.11, 15.3) 3.34 (0.73, 15.2) 5.74 (1.67, 19.7)
NRTIs use (mo)
 ≤6 (N=123) 1.00 1.00 1.00
6.1–18 (N=15) 1.48 (0.47, 4.68) 4.88 (1.08, 22.0) 0.60 (0.13, 2.85)
 >18 (N=38) 2.16 (1.01, 4.62) 4.40 (1.38, 14.0) 1.22 (0.51, 2.90)
NNRTIs use (mo)
 ≤6 (N=150) 1.00 1.00 1.00
6.1–18 (N=4) 9.16 (0.95, 90.8) 6.81 (0.63, 74.1) 4.00 (0.54, 29.6)
 >18 (N=22) 3.67 (1.46, 9.18) 11.7 (3.68, 37.0) 0.89 (0.28, 2.82)
PI use (mo)
 ≤6 (N=125) 1.00 1.00 1.00
 6.1–18 (N=18) 1.17 (0.39, 3.53) not estimable 1.71(0.55, 5.26)
 >18 (N=33) 2.85 (1.29, 6.32) 4.68 (1.60, 13.7) 1.42 (0.57, 3.55)
ART exposure (mo)
 ≤6 (N=96) 1.00 1.00 1.00 1.00 1.00
 6.1–18 (N=23) 0.88 (0.22, 3.47) 0.71 (0.16, 3.23) not estimable not estimable 1.04 (0.26, 4.14)
 >18 (N=57) 2.52 (1.24, 5.09) 2.20 (1.01, 4.79) 7.61 (1.67, 34.7) 7.61 (1.67, 34.7) 1.34 (0.62, 2.89)
*

Abbreviations: HIV = human immunodeficiency virus; CD4 = CD4 cell count; hsCRP = high sensitivity C reactive protein; BP = blood pressure; Glucose = fasting glucose; BMI = body mass index; LDL-C = low density lipoprotein cholesterol; HDL-C = high density lipoprotein cholesterol; Framingham score = Framingham risk score; NRTIs = nucleoside reverse transcriptase inhibitors; NNRTIs = nonnucleoside reverse transcriptase inhibitors; PIs = protease inhibitors; ART = antiretroviral therapy.